COVID-19 Coagulopathy Extension Study
Key facts
- Who runs it
- University of Iowa
- Where
- Iowa City, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 180 people, planned
- Started
- 21 Jan 2022
- Planned end
- 31 Dec 2025
- Type of study
- Observational, 3 groups
- Record updated
- 6 April 2025
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- Subjects must meet all inclusion criteria in one of the following three categories:
- Acute COVID-19; Hospital admission for management of symptoms related to COVID-19; Laboratory confirmed infection with SARS-CoV-2 by either PCR or antigen testing within 4 weeks of hospital admission; Age ≥18 years
- Incidental COVID-19; Hospital admission for indications unrelated to COVID-19 who are incidentally found to have infection with SARS-CoV-2; Age ≥18 years
- Acute influenza; Hospital admission for clinical management of symptoms related to influenza; Laboratory confirmed infection with influenza A or influenza B within 4 weeks of hospital admission; Negative testing for SARS-CoV-2; Age ≥18 years
Who cannot take part
- History of a bleeding disorder
- Active cancer
- Current pregnancy
- Prisoner
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Covid-19
This trial is currently available in United States.
- University of Iowa Health CareIowa City, United StatesContact: Katina WilsonTaking people
About the trial
What the trial wants to find out
At the University of Iowa, the investigators led a multicenter randomized clinical trial comparing standard prophylactic dose to intermediate dose enoxaparin in hospitalized patients with COVID-19 (NCT04360824). As part of an exploratory biomarker component of this trial, blood samples were collected from hospitalized COVID-19 patients at enrollment and weekly for up to 30 days of hospitalization. The pilot results, as well as reports from other groups, demonstrate increased potential for thrombin generation in the plasma of COVID-19 patients. In particular, in the COVID-19 patient cohort enhanced thrombin generation potential persisted for at least 30 days of hospitalization. The investigators now propose to explore the mechanistic roles of activation of blood cells (such as platelets and neutrophils) and products of cellular activation as mediators of enhanced thrombin generation in patients with COVID-19. The study design will be a longitudinal cohort study, which will allow for the determination of the time course of enhanced thrombin generation potential in relation to clinical outcomes and changes in markers of cellular activation in serial samples obtained from COVID-19 patients for up to 3 years after infection with SARS-CoV-2. This study may provide clues to why a subset of COVID-19 patients present with late thrombotic complications even after apparent recovery from SARS-CoV-2 infection. An ongoing question in the field relates to the comparative prothrombotic effects of acute COVID-19 versus incidental SARS-CoV-2 infection versus acute infection with influenza viruses. Therefore, we will include three categories of hospitalized patients in this study: (1) acute COVID-19, (2) incidental COVID-19, and (3) acute influenza A or B. This project has a strong scientific rationale with direct clinical implications, especially given the emergence of SARS-CoV-2 variants such as delta and omicron that may prolong the pandemic and/or cause surges of COVID-19 in the coming months.
The 3 groups in the trial
- Acute COVID-19
Hospital admission for management of symptoms related to COVID-19. Laboratory confirmed infection with SARS-CoV-2 by either PCR or antigen testing within 4 weeks of hospital admission. Age ≥18 years.
- Incidental COVID-19
Hospital admission for indications unrelated to COVID-19 who are incidentally found to have infection with SARS-CoV-2. Age ≥18 years.
- Acute influenza
Hospital admission for clinical management of symptoms related to influenza. Laboratory confirmed infection with influenza A or influenza B within 4 weeks of hospital admission. Negative testing for SARS-CoV-2. Age ≥18 years.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Cellular Effects of SARS-CoV-2 in Mediating Thrombotic Susceptibility
- Criteria questions
- Built from NCT05334615, who can take part
- Record updated
- 6 April 2025